• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

年轻镰状细胞病患者长期使用羟基脲治疗后胎儿血红蛋白和F细胞的反应。法国镰状细胞病研究小组。

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.

作者信息

Maier-Redelsperger M, de Montalembert M, Flahault A, Neonato M G, Ducrocq R, Masson M P, Girot R, Elion J

机构信息

Service d'Hématologie Biologique, Hôpital Tenon, Paris, France.

出版信息

Blood. 1998 Jun 15;91(12):4472-9.

PMID:9616141
Abstract

We have studied the cellular and molecular responses to long-term hydroxyurea (HU) treatment in 29 severely affected young patients with sickle cell disease (mean age, 10.9 +/- 4.1 years). Patients received HU at 20 mg/kg/d on 4 consecutive days per week initially, with a monthly escalated dose avoiding marrow-toxicity (mean steady-state dose, 34.2 +/- 4.6 mg/kg/d) for 12 to 36 months (mean duration, 22 months). The studied parameters were hemoglobin F (HbF), F reticulocytes (F retics), F cells, the amount of HbF per F cell (F/F cell), polymer tendency at 40% and 70% oxygen saturation, and hemolysis. Initial HbF (Fi) was dispersed (from 0.85% to 13.9%). HbF increased in all patients but 1. HbF at maximal response (Fmax) reached a sustained level varying from a 1.5-fold to a 16-fold Fi after a variable delay (6 to 24 months). Fmax was not related to HU dosage, but triangle upF (Fmax - Fi) was strongly correlated to triangle upMCV (MCVmax - MCVi). HbF increase resulted from the increase of both F cells and F/F cell. In this rather short series, Fi and Fmax were not significantly associated with age, gender, or beta-globin haplotype. Neither Fmax nor triangle upF was related to bone marrow reserve, as measured by baseline reticulocyte or neutrophil counts. However, Fmax was highly dependent on Fi. When patients are individualized into three groups according to Fmax (group 1, Fmax >20% [12 patients]; group 2, 10% < Fmax < 20% [11 patients]; group 3, Fmax <10% [5 patients]), Fi is significantly different between groups, being the highest in group 1. In addition, the best responders (group 1) were significantly different from patients in the two other groups with higher levels of total hemoglobin, decreased bilirubin, and decreased polymer tendency.

摘要

我们研究了29例重症镰状细胞病年轻患者(平均年龄10.9±4.1岁)对长期羟基脲(HU)治疗的细胞和分子反应。患者最初每周连续4天接受20mg/kg/d的HU治疗,每月递增剂量以避免骨髓毒性(平均稳态剂量34.2±4.6mg/kg/d),持续12至36个月(平均疗程22个月)。研究参数包括血红蛋白F(HbF)、F网织红细胞(F retics)、F细胞、每个F细胞的HbF量(F/F cell)、40%和70%氧饱和度下的聚合倾向以及溶血。初始HbF(Fi)分布范围较广(从0.85%至13.9%)。除1例患者外,所有患者的HbF均升高。最大反应时的HbF(Fmax)在不同延迟时间(6至24个月)后达到持续水平,为Fi的1.5倍至16倍。Fmax与HU剂量无关,但△F(Fmax - Fi)与△MCV(MCVmax - MCVi)密切相关。HbF升高是由于F细胞和F/F cell均增加。在这个相对较短的系列研究中,Fi和Fmax与年龄、性别或β珠蛋白单倍型无显著相关性。Fmax和△F均与通过基线网织红细胞或中性粒细胞计数测量的骨髓储备无关。然而,Fmax高度依赖于Fi。当根据Fmax将患者分为三组时(第1组,Fmax>20%[12例患者];第2组,10%<Fmax<20%[11例患者];第3组,Fmax<10%[5例患者]),各组间Fi存在显著差异,第1组最高。此外,最佳反应者(第1组)与其他两组患者在总血红蛋白水平更高、胆红素降低和聚合倾向降低方面存在显著差异。

相似文献

1
Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.年轻镰状细胞病患者长期使用羟基脲治疗后胎儿血红蛋白和F细胞的反应。法国镰状细胞病研究小组。
Blood. 1998 Jun 15;91(12):4472-9.
2
Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.接受羟基脲治疗的镰状细胞病患者的网织红细胞参数和血红蛋白F生成
J Clin Lab Anal. 2003;17(2):66-72. doi: 10.1002/jcla.10070.
3
Determinants of fetal hemoglobin response to hydroxyurea.胎儿血红蛋白对羟基脲反应的决定因素。
Semin Hematol. 1997 Jul;34(3 Suppl 3):8-14.
4
Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.接受羟基脲治疗的镰状细胞病患者胎儿血红蛋白反应谱:美国国立卫生研究院的经验
Semin Oncol. 1992 Jun;19(3 Suppl 9):67-73.
5
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.接受羟基脲治疗的镰状细胞贫血患儿胎儿血红蛋白反应的预测因素。
Blood. 2002 Jan 1;99(1):10-4. doi: 10.1182/blood.v99.1.10.
6
Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.镰状细胞贫血中的胎儿血红蛋白:对羟基脲反应的决定因素。羟基脲多中心研究。
Blood. 1997 Feb 1;89(3):1078-88.
7
Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.羟基脲与镰状细胞贫血。一种骨髓抑制性“转换”药物的临床应用。羟基脲治疗镰状细胞贫血多中心研究。
Medicine (Baltimore). 1996 Nov;75(6):300-26. doi: 10.1097/00005792-199611000-00002.
8
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.羟基脲在最大耐受剂量下对镰状细胞病患儿的长期血液学疗效。
Blood. 2004 Mar 15;103(6):2039-45. doi: 10.1182/blood-2003-07-2475. Epub 2003 Nov 20.
9
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.早期采用个体化药代动力学指导剂量的羟基脲(羟脲)治疗可使镰状细胞贫血儿童持续且几乎全细胞表达胎儿血红蛋白。
Br J Haematol. 2021 Aug;194(3):617-625. doi: 10.1111/bjh.17663. Epub 2021 Jul 5.
10
Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.羟基脲在成人镰状细胞贫血治疗中的作用机制。
Semin Hematol. 1997 Jul;34(3 Suppl 3):15-21.

引用本文的文献

1
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.早期采用个体化药代动力学指导剂量的羟基脲(羟脲)治疗可使镰状细胞贫血儿童持续且几乎全细胞表达胎儿血红蛋白。
Br J Haematol. 2021 Aug;194(3):617-625. doi: 10.1111/bjh.17663. Epub 2021 Jul 5.
2
Heterogeneity of fetal hemoglobin production in adult red blood cells.成人红细胞中胎儿血红蛋白生成的异质性。
Curr Opin Hematol. 2021 May 1;28(3):164-170. doi: 10.1097/MOH.0000000000000640.
3
and induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor.
以及使用可逆性和选择性DNA甲基转移酶1(DNMT1)抑制剂诱导胎儿血红蛋白。
Haematologica. 2021 Jul 1;106(7):1979-1987. doi: 10.3324/haematol.2020.248658.
4
Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts.通过比较 F 和 A 红细胞来理解胎儿血红蛋白诱导的异质性。
Blood. 2020 May 28;135(22):1957-1968. doi: 10.1182/blood.2020005058.
5
A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease.一种新型、高效、选择性的磷酸二酯酶-9 抑制剂,用于治疗镰状细胞病。
Haematologica. 2020 Mar;105(3):623-631. doi: 10.3324/haematol.2018.213462. Epub 2019 May 30.
6
MIR29B mediates epigenetic mechanisms of HBG gene activation.MIR29B 介导 HBG 基因激活的表观遗传机制。
Br J Haematol. 2019 Jul;186(1):91-100. doi: 10.1111/bjh.15870. Epub 2019 Mar 19.
7
Development and Characterization of a Model for Inducing Fetal Hemoglobin Production in Cynomolgus Macaques ().食蟹猕猴中诱导胎儿血红蛋白产生模型的建立与表征()
Comp Med. 2018 Oct 1;68(5):396-402. doi: 10.30802/AALAS-CM-17-000124. Epub 2018 Aug 9.
8
Emerging point-of-care technologies for sickle cell disease screening and monitoring.用于镰状细胞病筛查和监测的新兴即时检测技术。
Expert Rev Med Devices. 2016 Dec;13(12):1073-1093. doi: 10.1080/17434440.2016.1254038. Epub 2016 Nov 22.
9
Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.一项随机对照试验的研究方案,旨在评估开放标签干预措施改善镰状细胞病青少年羟基脲依从性的可行性。
Contemp Clin Trials. 2016 Jul;49:134-42. doi: 10.1016/j.cct.2016.06.004. Epub 2016 Jun 17.
10
A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.对羟基脲诱导胎儿血红蛋白治疗镰状细胞病已知机制的系统评价。
Expert Rev Hematol. 2015 Oct;8(5):669-79. doi: 10.1586/17474086.2015.1078235. Epub 2015 Sep 1.